Healthcare Industry News: brachytherapy
News Release - September 13, 2007
Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy CommunityNewly Independent Radiation Oncology Company Emerges as Industry Leader with Distinct Focus on Partnership, Innovation and Integration
VEENENDAAL, The Netherlands, Sept. 13 (HSMN NewsFeed) -- Nucletron announced today the successful management buy-out from Delft Instruments, creating an independent company fully dedicated to radiation oncology. Since its inception in 1974, Nucletron has operated several entities in the field of radiation oncology throughout the world. The consolidation of the various entities into one, focused company further establishes Nucletron in a leadership role in this rapidly changing field. Collaborative partnerships, pioneering research and development of advanced technological innovations will enable Nucletron to more effectively deliver cancer treatment solutions globally and set the company apart within the industry.
"The creation of an independent Nucletron is the result of the company's success in the past two years," said David Imperiali, chief executive officer of Nucletron. "Nucletron has a strong tradition of innovation in radiotherapy, and the breadth of our capability positions the company well to continue to make significant contributions to the treatment of cancer."
The previous company, under Delft Instruments, was created in 1994 by merging Nucletron, the global leader in brachytherapy solutions, with the Oldelft Simulix(TM) brand of radiation therapy simulation and imaging technology. Additionally, in 2003, Nucletron integrated the Helax and Theratronics treatment planning and management solutions, from MDS Nordion, into its portfolio to create Oncentra® MasterPlan(TM) and Oncentra® Information Management.
"Nucletron's ability to restructure itself, anticipate needs, and incorporate new state-of-the-art products and services into our solutions suite gives us the ability to create strong and long-lasting relationships with our customers and partners," said Jeroen Cammeraat, chief operating officer of Nucletron. "The new corporate structure gives us the flexibility and agility to continue to develop world-class solutions for our customers and partners, focused on improving patient care."
With more than 10 percent of its revenues invested in research and development, Nucletron continuously seeks improvement of its existing product range and creation of new treatment options that improve patients' quality of care through curative and palliative treatment. The company's continued efforts in R&D, both in-house and through partnerships with leading academic institutions, have resulted in a strong and unique IP base.
Headquartered in The Netherlands, Nucletron delivers customized solutions to more than 3,000 institutions in more than 120 countries, equating to global sales of euro 120 million ($160 million), with operating profit levels that rank in the upper quartile of the industry. Worldwide, Nucletron has offices in 16 countries, including a production and R&D facility in The Netherlands, R&D centers in Uppsala, Sweden and Oslo, Norway and sales, marketing, service and support operations in Europe, Asia, Australia and North America.
The supervisory board of Nucletron will be chaired by Rob Westerhof, who has held senior positions in Asia and in the USA for Philips Medical Systems and Philips Electronics. Commenting on the spin-off, Westerhof stated, "I am excited to join Nucletron's supervisory board. Being involved in the medical business for more than 15 years in various positions throughout the world, I trust that I can make a contribution. Nucletron represents a strong brand in the world of oncology and related areas, and there are excellent opportunities for expanding our market share. I am looking forward to working with the new management team and further strengthening Nucletron."
Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. The investors in the independent Nucletron company include AlpInvest Partners, Advent International, the Nucletron Management and Employees. For more information, visit www.nucletron.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.